A comprehensive genomic study has unveiled critical insights into the natural history and progression patterns of chronic blood cancers, notably myeloproliferative neoplasms (MPNs). Researchers from the Wellcome Sanger Institute, in collaboration with clinical teams at Cambridge University Hospitals NHS Foundation Trust, have traced the genetic evolution of blood cell populations over extended periods, demonstrating how distinct mutational landscapes can predict disease stability or progression. This pioneering work, published in Cancer Discovery, underscores the transformative potential of integrating longitudinal genomic surveillance into routine clinical management to anticipate and intercept blood cancer progression years in advance.
Myeloproliferative neoplasms, a rare class of chronic blood malignancies, arise from the excessive and disordered production of blood cells in the bone marrow. Affecting approximately 40,000 individuals in the UK—with about 4,000 new diagnoses annually—MPNs typically evolve slowly and are driven by mutations in key genes such as JAK2, CALR, and MPL. However, a notable subset of patients lack these canonical genetic markers, complicating diagnostic accuracy and therapeutic decision-making. Presently, diagnosis in these cases relies heavily on morphological examination of bone marrow cells, which may inadvertently lead to unnecessary or insufficient treatment interventions.
In the recent study, scientists employed whole-genome sequencing (WGS) alongside deep clinical phenotyping, analyzing over 450 longitudinal blood samples collected from 30 patients over a span reaching 25 years. The integration of nearly 8,000 serial blood test results, detailed treatment histories, and disease progression data allowed for an unprecedented reconstruction of the clonal architecture and mutational trajectories within hematopoietic populations. By leveraging phylogenetic methods to construct cellular “family trees,” the team successfully mapped the emergence and expansion of genetically homogeneous cancer clones responsible for disease advancement.
A striking discovery was the delineation of two divergent evolutionary paradigms within MPN patients. Individuals whose disease remained clinically quiescent exhibited blood cell populations with remarkably stable genomic profiles, acquiring minimal or no additional mutations over time. Conversely, patients who experienced clinical deterioration showed progressive accrual of somatic mutations within these clones, implicating the genetic changes as prognostic indicators encoded well before symptomatic manifestation. This revelation suggests that genomic instability and clonal evolution function as early harbingers of malignancy progression in chronic blood cancers.
Equally compelling was the insight gleaned from patients lacking the hallmark JAK2, CALR, or MPL mutations. Their blood cell lineages displayed mutational patterns and evolutionary dynamics consistent with normal hematopoietic aging rather than malignant transformation. This finding disrupts prevailing assumptions that certain bone marrow abnormalities always equate to true blood cancer, highlighting the necessity for refined diagnostic criteria. Consequently, it supports emerging British Society for Haematology guidelines that advocate for distinguishing between thrombocytosis without driver mutations and bona fide MPNs, fostering more personalized and accurate patient management.
The implications of these findings are multifaceted. First, they advocate for the adoption of regular genomic monitoring in clinical practice to enable risk stratification and earlier intervention in patients predisposed to progression. Second, they illuminate potential molecular targets for novel therapeutic strategies aimed at curbing clonal expansion before clinical decline ensues. Lastly, they encourage the reassessment of diagnostic frameworks, minimizing overtreatment while ensuring those at genuine risk receive appropriate care.
Dr. Daniel Leongamornlert, the study’s lead author from the Wellcome Sanger Institute, emphasized the power of integrating genomic data with longitudinal clinical observations, stating that this approach has revealed distinct evolutionary contours that differentiate stable from progressing MPN cases. This methodology provides a blueprint to decode cancer’s developmental blueprint directly from patient samples—an advancement with far-reaching prognostic and therapeutic ramifications.
Cancer Research UK’s Dr Dani Skirrow highlighted the broader context of this work within the genomics revolution, noting that rapid DNA sequencing technologies now allow researchers to capture the mutational narratives underlying cancer initiation and development. These high-resolution molecular portraits not only deepen biological understanding but also accelerate the translation of discoveries into clinical tools that enhance early detection and personalized care.
From the clinical perspective, Dr Jyoti Nangalia, senior author and consultant haematologist, reflected on the challenges faced in predicting MPN trajectories and how this robust genomic analysis coupled with clinical data promises to refine monitoring paradigms and improve patient outcomes. Their ability to trace the genetic evolution decades prior to clinical milestones offers a transformative lens through which to view cancer management.
A poignant patient narrative is provided by Alan Everitt, diagnosed with essential thrombocythaemia (ET) in 1992, who experienced progression to myelofibrosis and subsequent complications such as skin cancers over time. His long-term engagement with clinical teams at Addenbrooke’s Hospital exemplifies the value of sustained patient care integrated with research, underscoring the real-world benefits of such studies and their potential to inform future therapies that could alter disease courses for others.
This landmark investigation is a testament to the power of combining genomics with longitudinal clinical follow-up to dissect the complexities of blood cancer evolution. The elucidation of genetically ‘steady’ versus ‘progressive’ disease forms paves the way for deploying precision medicine approaches that could revolutionize how chronic blood cancers are diagnosed, monitored, and treated—ultimately extending patient survival and quality of life.
The study’s contributions align with the ethos of open science championed by the Wellcome Sanger Institute and its partners, underscoring a commitment to data sharing and collaborative efforts that drive forward genomics-driven healthcare. Funded by Wellcome and Cancer Research UK, this research sets a new standard in leveraging integrative genomics to decode cancer’s life history, highlighting a future where routine genomic surveillance transforms oncology from reactive to proactive practice.
Subject of Research: Genomic evolution and disease progression in chronic blood cancers, specifically myeloproliferative neoplasms (MPNs)
Article Title: Genomic evolution and natural history of myeloproliferative neoplasms on therapy
News Publication Date: 20-Apr-2026
Web References:
- Wellcome Sanger Institute
- Blood Cancer UK
- British Society for Haematology guidelines on thrombocytosis
References:
- Williams et al., Nature (2022); DOI: 10.1038/s41586-021-04312-6
- Godfrey et al., British Journal of Haematology (2026); DOI: 10.1111/bjh.70260
- Leongamornlert et al., Cancer Discovery (2026); DOI: 10.1158/2159-8290.CD-26-0410
Keywords: Blood cancer, myeloproliferative neoplasms, genomics, genomic evolution, cancer progression, whole-genome sequencing, clonal hematopoiesis, precision medicine, cancer diagnostics, longitudinal genomic monitoring
